3,450 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by Triglav Skladi D.O.O.

Triglav Skladi D.O.O. purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 3,450 shares of the pharmaceutical company's stock, valued at approximately $1,389,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. ABC Arbitrage SA bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $1,510,000. Highview Capital Management LLC DE increased its holdings in shares of Vertex Pharmaceuticals by 1.8% in the 4th quarter. Highview Capital Management LLC DE now owns 5,771 shares of the pharmaceutical company's stock valued at $2,324,000 after acquiring an additional 102 shares during the last quarter. Davidson Investment Advisors increased its holdings in shares of Vertex Pharmaceuticals by 26.0% in the 4th quarter. Davidson Investment Advisors now owns 61,161 shares of the pharmaceutical company's stock valued at $24,630,000 after acquiring an additional 12,631 shares during the last quarter. Jones Financial Companies Lllp increased its holdings in shares of Vertex Pharmaceuticals by 75.5% in the 4th quarter. Jones Financial Companies Lllp now owns 2,468 shares of the pharmaceutical company's stock valued at $994,000 after acquiring an additional 1,062 shares during the last quarter. Finally, Concord Wealth Partners increased its holdings in shares of Vertex Pharmaceuticals by 32.6% in the 4th quarter. Concord Wealth Partners now owns 3,508 shares of the pharmaceutical company's stock valued at $1,413,000 after acquiring an additional 862 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 530 shares of the firm's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $475.34, for a total value of $251,930.20. Following the completion of the sale, the executive vice president now directly owns 58,539 shares in the company, valued at $27,825,928.26. This trade represents a 0.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the transaction, the executive vice president now owns 26,512 shares of the company's stock, valued at $13,256,000. This trade represents a 10.86% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,813 shares of company stock valued at $1,889,514. Corporate insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Price Performance

Shares of VRTX traded down $11.86 during trading hours on Wednesday, reaching $435.32. The stock had a trading volume of 1,427,271 shares, compared to its average volume of 1,413,483. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The stock has a market capitalization of $111.79 billion, a PE ratio of -197.87, a PEG ratio of 2.11 and a beta of 0.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The company's 50-day moving average is $479.38 and its two-hundred day moving average is $463.83.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.29 by ($0.23). The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The firm's revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the business earned $4.76 earnings per share. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $535.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Scotiabank reduced their price objective on Vertex Pharmaceuticals from $450.00 to $442.00 and set a "sector perform" rating for the company in a research report on Tuesday, May 6th. Bank of America boosted their price objective on Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a "buy" rating in a research report on Monday, March 31st. JPMorgan Chase & Co. boosted their price objective on Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an "overweight" rating in a research report on Tuesday, May 6th. Finally, Royal Bank of Canada boosted their price objective on Vertex Pharmaceuticals from $420.00 to $423.00 and gave the company a "sector perform" rating in a research report on Tuesday, May 6th. Thirteen investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $515.04.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.